Key result
Two young males developed acute myopericarditis with a benign clinical course three days after receiving the second dose of the mRNA-1273 COVID-19 vaccine.
Case Report (n=2)
No
The mRNA-1273 COVID-19 vaccine can rarely cause acute myopericarditis in young males, typically presenting a few days after the second dose with a benign clinical course.
Prompts vigilance for myopericarditis in young males post-mRNA-1273; leaves incidence and causality open.
Background: Cases of myocarditis and myopericarditis after mRNA COVID-19 vaccines have been reported, especially after the second dose and in young males. Their course is generally benign, with symptoms onset after 24-72 h from the dose. Case Summary: We report two cases of myopericarditis after the second dose of the mRNA-1273 COVID-19 vaccine in two young males. Both the patients were administered the mRNA-1273 COVID-19 vaccine from the same batch on the same day and experienced fever on the same day of the vaccine, and symptoms consisted of myopericarditis 3 days after the dose. Discussion: Myopericarditis is usually considered an uncommon adverse reaction after various vaccinations, reported also after the mRNA COVID-19 vaccine. Several explanations have been proposed, including an abnormal activation of the immune system leading to a pro-inflammatory cascade responsible for myocarditis development. Both patients experienced the same temporal onset as well as the same symptoms, it is also useful to underscore that both vaccines belonged to the same batch of vaccines. However, despite these cases, vaccination against COVID-19 far outweighs the risk linked to COVID-19 infection and remains the best option to overcome this disease.
No takes yet. Share an insight, caveat, or question.
Sciaccaluga et al. (2022) conducted a case report in Acute myopericarditis (n=2). mRNA-1273 COVID-19 vaccine was evaluated on Development of acute myopericarditis. Two young males developed acute myopericarditis with a benign clinical course three days after receiving the second dose of the mRNA-1273 COVID-19 vaccine.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: